Kymera Therapeutics, Inc.
KYMR
$22.25
-$1.44-6.08%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.39M | 3.74M | 25.65M | 10.29M | 47.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.39M | 3.74M | 25.65M | 10.29M | 47.89M |
| Cost of Revenue | 71.82M | 60.41M | 59.20M | 48.82M | 52.97M |
| Gross Profit | -64.42M | -56.67M | -33.55M | -38.53M | -5.09M |
| SG&A Expenses | 16.33M | 15.46M | 17.37M | 14.37M | 14.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.15M | 75.87M | 76.58M | 63.19M | 67.20M |
| Operating Income | -80.76M | -72.12M | -50.93M | -52.91M | -19.31M |
| Income Before Tax | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M |
| EBIT | -80.76M | -72.12M | -50.93M | -52.91M | -19.31M |
| EBITDA | -80.17M | -70.14M | -48.99M | -51.45M | -18.80M |
| EPS Basic | -0.88 | -0.82 | -0.58 | -0.69 | -0.25 |
| Normalized Basic EPS | -0.55 | -0.51 | -0.36 | -0.39 | -0.15 |
| EPS Diluted | -0.88 | -0.82 | -0.58 | -0.69 | -0.25 |
| Normalized Diluted EPS | -0.55 | -0.51 | -0.36 | -0.39 | -0.15 |
| Average Basic Shares Outstanding | 79.99M | 76.13M | 73.06M | 70.77M | 58.52M |
| Average Diluted Shares Outstanding | 79.99M | 76.13M | 73.06M | 70.77M | 58.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
